Vaccine Therapy in Treating Young Patients Who Are Undergoing Surgery for Malignant Glioma

Inclusion Criteria:

* Histologically confirmed\* WHO grade III or IV malignant glioma of 1 of the following subtypes:
* Anaplastic astrocytoma
* Anaplastic oligodendroglioma
* Glioblastoma multiforme NOTE: \*Must be confirmed after surgery
* Newly diagnosed OR recurrent disease
* Bidimensionally measurable disease by contrast-enhancing pre-operative MRI
* Surgically accessible tumor for which surgical resection is indicated at the time of initial pre-operative evaluation
* Must have undergone standard surgery\* AND either radiotherapy\* or chemoradiotherapy\*
* Objective evidence of disease by contrast-enhanced brain MRI after completion of standard therapy NOTE: \*Completed after study entry but before assignment to study treatment cohorts
* Age 1 to 18
* Performance status Karnofsky 60-100%
* Hematopoietic

  * Hemoglobin ≥ 10 g/dL
  * Absolute granulocyte count ≥ 1,500/mm\^3
  * Platelet count ≥ 100,000/mm\^3
* Hepatic

  * SGPT and SGOT ≤ 2 times normal
  * Alkaline phosphatase ≤ 2 times normal
  * Bilirubin ≤ 1.5 mg/dL
  * Hepatitis B and C negative
* Renal

  * BUN ≤ 1.5 times normal OR
  * Creatinine ≤ 1.5 times normal
* Immunologic

  * HIV negative
  * Syphilis negative
* At least 2 weeks since prior radiotherapy and recovered
* Negative pregnancy test
* Fertile patients must use effective contraception
* More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered
* No chemotherapy during and for 4 weeks\* after the final dose of study vaccine
* No corticosteroids for at least 10 days before leukapheresis
* No concurrent corticosteroids
* More than 72 hours since prior systemic antibiotics
* No antihistamines for 5 days before and for 5 days after administration of study vaccine

Exclusion Criteria:

* history of immunodeficiency or autoimmune disease that may be exacerbated by immunotherapy, including any of the following:
* Rheumatoid arthritis
* Systemic lupus erythematosus
* Vasculitis
* Polymyositis
* Dermatomyositis
* Scleroderma
* Multiple sclerosis
* Juvenile-onset insulin-dependent diabetes
* active infection
* fever
* allergy to study reagents
* pregnant or nursing
* other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, localized prostate cancer, or carcinoma in situ of the cervix
* unstable or severe medical or psychiatric condition, as determined by the investigator
* underlying condition that would preclude study participation
* concurrent radiotherapy
* prior organ allograft
* concurrent strong painkillers
* other concurrent immune-suppressing medications
* other concurrent investigational agents
* other adjuvant treatment for 4 weeks\* after the final dose of study vaccine NOTE: \*Unless there is evidence of tumor progression necessitating additional clinically-indicated treatment; patients requiring treatment due to tumor progression are removed from the study